Fig. 6

Inactivation of HSCs by the Canakinumab. Staining with Oil Red O shows an increase in the content of lipid droplets in LX-2 cells treated with Canakinumab. The inhibition of IL-1β by Canakinumab promotes the inactivation of HSCs as demonstrated by the accumulation of lipid droplets in the cytoplasm. The images are representative of one of three experiments performed with Oil Red O staining